Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4928116 | 0.87 | MAPT (0.37) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL1902569 | 0.84 | MAPT (0.47) | MAPTGAARAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31448339 | 0.77 | MAPT (0.43) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL28059865 | 0.77 | MAPT (0.43) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL10471539 | 0.76 | NISCH (0.39) | ALDH1A1HPGDLMNACACNA1FSCN1A | |
| SCHEMBL4796337 | 0.76 | MAPT (0.42) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL29896250 | 0.76 | MAPT (0.42) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL1902325 | 0.75 | PTGS2 (0.39) | MAPTRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9782872 | 0.75 | MAPT (0.41) | MAPTGAARAB9ASMN1; SMN2P2RX4 | |
| SCHEMBL984966 | 0.75 | MAPT (0.41) | MAPTGAARAB9ASMN1; SMN2P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0916658-B1 | Assays utilizing improved chemiluminescent esters, thioesters and amides | NICHOLS INST DIAGNOSTICS (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2004031321-A1 | OXYGEN SENSING COMPOUNDS, METHODS FOR PRODUCTION THEREOF AND THEIR USES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2004-04-15 | — | — | WO | disclosed |
| EP-0322926-B2 | Assays utilizing improved chemiluminescent esters, thioesters and amides | NICHOLS INST DIAGNOSTICS (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6624175-B2 | 4-heterocyclic substituted quinoline derivative treats disorderes associated with pathogenic neurokinin-3 receptor, such as anxiety, depression, schizophrenia, obesity, chronic pulmonary obstructive disorder or pain | NEUROGEN CORPORATION | 2003-09-23 | — | — | US | disclosed |
| EP-1165542-B1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2003-08-20 | — | — | EP | disclosed |
| US-20020198232-A1 | 4-substituted quinoline derivatives | NEUROGEN CORPORATION (US) | 2002-12-26 | — | — | US | disclosed |
| WO-2000058303-A9 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORP (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6413982-B1 | 5-ETHYL-5-PHENYL-2-(3-METHOXY-2-PHENYLQUINOLIN-4-YL)-IMIDAZO -LINE; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISEASES AND DISORDERS; BINDS WITH HIGH AFFINITY TO NEUROKININ-3 (NK-3) AND/OR GAMMA-AMINOBUTYRIC ACID RECEPTORS; SYNERGISTIC | NEUROGEN CORPORATION | 2002-07-02 | — | — | US | disclosed |
| EP-1165542-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058303-A1 | 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2000-10-05 | — | — | WO | disclosed |
| EP-0322926-B1 | Assays utilizing improved chemiluminescent esters, thioesters and amides | NICHOLS INST DIAGNOSTICS (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0916658-A1 | Assays utilizing improved chemiluminescent esters, thioesters and amides | Nichols Institute Diagnostics (US) | 1999-05-19 | — | — | EP | disclosed |
| US-5284952-A | Sulfonyl substituted chemiluminescent labels and their conjugates, and assays therefrom | LONDON DIAGNOSTICS, INC. (US) | 1994-02-08 | — | — | US | disclosed |
| US-5284951-A | Aryl ester, thioester or amide of carboxylic acid substituted heterocyclic ring; quaternary compounds | LONDON DIAGNOSTICS, INC. (US) | 1994-02-08 | — | — | US | disclosed |
| WO-1989006231-A1 | ASSAYS UTILIZING IMPROVED CHEMILUMINESCENT ESTERS, THIOESTERS AND AMIDES | LONDON DIAGNOSTICS, INC. (US) | 1989-07-13 | — | — | WO | disclosed |
| EP-0322926-A2 | Assays utilizing improved chemiluminescent esters, thioesters and amides | LONDON DIAGNOSTICS, INC. (US) | 1989-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198232-A1 | 4-substituted quinoline derivatives | GABRA3, GABRB3, GABRR3 | MAPT 2766/4885GAA 956/4885AKR1C1 635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.